In adult muscle, acetylcholine receptors (AChR) are restricted mainly to the motor endplate where the adult isoform (abde) is expressed. When skeletal muscle is denervated in animal models, there is atrophy of the muscle and a marked increase in expression of the AChR foetal isoform (abgd) containing a g-subunit. Similar changes in AChR expression are thought to occur in human muscle. While the role of denervation in regulating AChR gene expression has been widely studied, it has not been determined whether the transcriptional programmes responsible for de®ning different ®bre types have an impact on the expression of AChR genes. We investigated biopsies from patients with a wide spectrum of neuromuscular diseases for expression of the AChR a-and g-subunits using RNase protection assays, a/g-duplex reverse transcriptase polymerase chain reaction, immunohistochemistry for foetal AChR and RNA in situ hybridization. Muscle from all patients with neurogenic disorders and, to a lesser extent, myogenic disorders, exhibited markedly increased transcription of the AChR g-subunit but, in contrast to previous animal studies, did not show increased AChR a-subunit. Moreover, both immunohistochemistry and RNA in situ hybridization revealed that AChR g-subunit hyperexpression occurred exclusively in atrophic type 1 and not in atrophic type 2 muscle ®bres, irrespective of the underlying neuromuscular disease. We conclude that up-regulation of the AChR g-subunit in human muscle disorders is restricted to type 1 muscle ®bres and, therefore, that AChR g-subunit expression is controlled by a muscle ®bre type-restricted transcriptional programme. The factors in¯uencing expression of this and other functional proteins should be relevant to the understanding and treatment of a range of neuromuscular disorders.
Introduction
The nicotinic acetylcholine receptors (AChR) of skeletal muscle are a pentameric ion channel composed of four different subunits (Changeux, 1992; Changeux et al., 1992) . Many studies on small mammals have shown that during development of the neuromuscular junction, a change from the foetal type (abgd) to the adult type (abed) occurs with replacement of the g-subunit by the e-subunit (Mishina et al., 1986; Witzemann et al., 1987 Witzemann et al., , 1989 . A similar change occurs during late gestation in humans (Hesselmans et al., 1993) and, in the adult, the foetal type of the AChR is found mainly on myoid cells in the thymus (Marx et al., 1989; Hara et al., 1993) and in some extraocular muscle ®bres (Horton et al., 1993; Kaminski et al., 1996; MacLennan et al., 1997) . In other adult human innervated muscles, only extremely low levels of AChR g-subunit transcripts have been detected by RNase protection assays or reverse transcriptase±polymerase ã Guarantors of Brain 2002 Brain (2002 , 125, 1309±1319 chain reaction (RT±PCR) (MacLennan et al., 1997; Gattenloehner et al., 1998 Gattenloehner et al., , 1999 and not by less sensitive Northern blotting (Geuder et al., 1992) .
Re-expression of the foetal type occurs after experimental denervation by nerve section or crush (Witzemann et al., 1989) . Similarly, in human conditions that result in severe lower motor neurone dysfunction, such as amyotrophic lateral sclerosis (Tsujihata et al., 2001) or diabetic neuropathy (Vincent and Newsom-Davis, 1982) , there is increased expression of foetal AChR. However, despite many studies concerning AChR gene expression in rodents (Whiting et al., 1986; Changeux, 1992; Changeux et al., 1992; Witzemann et al., 1989 Witzemann et al., , 1990 Witzemann et al., , 1991 , little is known about the factors that control human AChR expression.
In muscle biopsies from patients, histochemistry is used to distinguish type 1 (slow twitch or red) and type 2 (fast twitch or white) ®bres (Johnson et al., 1973; Round et al., 1980) . Type 1 ®bres contain more mitochondria and myoglobin, and utilize aerobic oxidation for their energy requirement, whereas type 2 ®bres contain more glycogen and produce energy through the anaerobic pathway. The molecular factors that govern ®bre type are not well characterized, but it is thought that distinct pathways are involved in type 1 and type 2 ®bres (Olson and Williams, 2000; Buckingham, 2001) . Whether the AChR genes are targets of these ®bre typerelated signalling cascades has not been investigated but, more than 30 years ago, Miledi and Zelena (Miledi and Zelena, 1966) showed that expression of AChR sensitivity along innervated rat muscle ®bres was detectable in thè slow' (i.e. type 1) soleus muscle, but not in`fast' (i.e. type 2) muscles. At that time, the distinction between adult and foetal AChRs had not been made.
We have recently shown that AChR g-subunit expression can be a useful tool in the diagnosis of rhabdomyosarcomas (Gattenloehner et al., 1998 (Gattenloehner et al., , 1999 . Here we applied similar approaches to look for AChR g-subunit and foetal AChR expression in muscle biopsies from patients undergoing routine investigations for muscle and nerve disorders. Our results show up-regulation of AChR g-subunit expression in many neurogenic and also in some myogenic disorders. Surprisingly, up-regulation was only found in type 1 ®bres, irrespective of the underlying disease, and foetal AChR expression was also restricted to atrophic type 1 ®bres.
Materials and methods Biopsies
Seventy-seven muscle biopsies (15 from patients with neurogenic disorders, 23 from patients with non-in¯amma-tory myopathies, eight from patients with in¯ammatory myopathy and 31 biopsies that were histologically normal) were obtained for frozen sections from patients undergoing routine investigations. All specimens came from the Departments of Surgery, Orthopedics or Neurology of the University of Wu Èrzburg (Wu Èrzburg, Germany) and were frozen within 15 min after biopsy. After frozen sections had been obtained, the tissue was immediately stored at ±80°C for long-term storage. The biopsies were kept on dry ice when being handled. A comparison of RT±PCR data from biopsies taken 3 years apart showed that the storage conditions did not in¯uence relative levels of the AChR a-and g-subunit transcripts (data not shown). All patients gave informed consent and ethical approval for the use of human muscle biopsies was received from the University of Wu Èrzburg Ethics Committee (contract C-16 of the IZKF). Clinical data and diagnoses are given in Table 1 . This information was disclosed to the experimental investigators (S.G. and A.M.) only at the end of the experiments by the participating neurologist (Dr C. Schneider).
Molecular biology
RNA isolation, cDNA-synthesis and the three-step immunoperoxidase-based immunohistochemistry procedure were performed as previously described (Gattenloehner et al., 1998; Marx et al., 1989) . For the simultaneous ampli®cation of the aAChR and gAChR mRNA, we used a duplex RT±PCR technique with primers speci®c for the aAChR and gAChR as described by Gattenloehner et al. (1999) . To quantify the aAChR and gAChR transcripts, we scanned the ethidium bromide-stained gel of RT±PCR products with an Agfa Scanner Arcus II (Duffenhofer, Wu Èrzburg, Germany) and measured the intensity using NIH (MacIntosh) software (FMS Software, Wu Èrzburg, Germany) by creating standard areas in which the extinction was calculated (Gattenloehner et al., 1999) .
For the RNase protection assay, total RNA was processed according to Pharmingen's RiboQuant protocol using antisense RNA as the probe. For the probes, PCR products were generated using primers speci®c for the AChR a-and gsubunits as well as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (aAChR upper primer (UP): 5¢-AAG CTA CTG TGA GAT CAT CGT-3¢; aAChR lower primer (LP): 5¢-TGA CGA AGT GGT AGG TGA TGT-3¢; gAChR UP: 5¢-ATC TCT GTC ACC TAC TTC CCC-3¢; gAChR LP: 5¢-AAG TGG ATG AGG ATG GCG ACA-3¢; GAPDH UP: 5¢-CAA CAG CGA CAC CCA CTC CTC-3¢; GAPDH LP: 5¢-CAT GTG GGC CAT GAG GTC CAC CAC-3¢). PCR products were cloned in a pGEM T-vector (Promega, Heidelberg, Germany) and sequenced by the cycle sequencing method using dye terminators and the ABI 373 sequencer (Applied Biosystems, Weiterstadt, Germany), following the manufacturer's instructions. The predicted length of the transcripts were: GAPDH unprotected, 233 bp, and protected, 156 bp; AChR a subunit unprotected, 334 bp, and protected, 244 bp; AChR g-subunit unprotected, 306 bp, and protected, 254 bp (because of an internal PstI site) (Fig. 1) . Patients within the groups of neurogenic disorders, non-in¯ammatory myopathies and in¯ammatory myopathies are listed according to an increasing ratio of AChR g-and a-subunit transcripts (g/a-ratio) as detected by RT±PCR. ALS = amyotrophic lateral sclerosis; ClChMyot = chloride channel myotonia; CIDP = chronic in¯ammatory demyelinating polyneuropathy; CPEO = chronic progressive external ophthalmoplegia; DM1 = myotonic dystrophy type 1; HNPP = hereditary neuropathy with liability to pressure palsies; IBM = inclusion body myositis; IH = immunohistochemistry; ISH = in situ hybridization; LGMD = limb girdle muscular dystrophy; LMND = lower motor neurone disease; MCP = mitochondrial cytopathy; MD = muscle dystrophy; MM = mononeuritis multiplex; MMP = mitochondrial myopathy; NA = not available; NB = neuroborreliosis; ND = not determined; PAN = panarteritis nodosa PM = polymyositis; PNP = polyneuropathy; PROMM = proximal myotonic dystrophy; SMAPN = sensori-motor axonal peripheral neuropathy.
Histochemical muscle ®bre typing
To identify the muscle ®bre subtype expressing the g-subunit of the AChR, serial histological sections of muscle biopsies were studied by enzyme histochemistry for ATPase reactions at pH 4.6 and pH 9.4 followed by immunohistochemistry for foetal AChR expression using a monoclonal antibody, mAbM1B8 (Jacobson et al., 1999) . Two different sections were stained from each case investigated (see Table 1 ).
In situ hybridization
The in situ hybridization procedure was as previously described (Czub et al., 1996) . Like the immunohistochemical studies, this part of the investigation was performed in a blind fashion, since we were neither aware of the diagnoses nor the immunohistochemical or enzyme histochemical ®ndings. From all cases investigated (see Table 1 ), four different sections were hybridized [two sections each for short-term (1 week) and long-term (4 weeks) exposure]. For the gAChR speci®c probe, a PCR product was generated using AChR gsubunit speci®c primers: gAChR UP: 5¢-ATC TCT GTC ACC TAC TTC CCC-3¢; gAChR LP: 5¢-AAG TGG ATG AGG ATG GCG ACA-3¢. The PCR product was cloned into the pGEMT vector and sequenced by the cycle sequencing method using dye terminators and the ABI 373 sequencer according to the manufacturer's instructions.
Results

g-Subunit but not a-subunit transcripts are increased in chronic neurogenic disorders
To quantify AChR transcription in various human muscle disorders, RNase protection assays were performed on the nine biopsies of suf®cient size for at least three independent determinations with both a-and g-probes. These biopsies consisted of three from patients with neurogenic disorders and two each from patients with in¯ammatory myopathies, non-in¯ammatory myopathies or histologically-normal muscle (control muscle). The muscles from which the biopsies were taken are shown in Table 1 .
As shown in Fig. 1 , all muscle biopsies, irrespective of the underlying pathology, showed AChR a-subunit mRNA expression that was not signi®cantly different from that in the normal biopsies. By contrast, the AChR g-subunit was dramatically increased in muscle biopsies derived from patients with neurogenic disorders. When the AChR a-and g-subunit-speci®c bands were quanti®ed by measuring their extinction, a 30±100-fold overexpression of the g-subunit AChR was shown in muscle biopsies from patients suffering from neurogenic disorders compared with control muscle biopsies (data not shown). However, none of the muscle biopsies derived from in¯ammatory or non-in¯ammatory myopathies exhibited signi®cant overexpression of AChR g-subunit message by RNase protection assay (e.g. Fig. 1 ).
Quantitative analysis of AChR g-subunit mRNA by AChR a/g-directed duplex PCR Application of RNase protection assays is limited by the relatively high quantity of RNA required for the assay, i.e. by biopsy size. To extend the studies to a larger series of muscle biopsies and to increase the sensitivity of AChR g-subunit transcript detection, we used a multiplex RT±PCR strategy to detect AChR a-and g-ubunit message simultaneously (Gattenloehner et al., 1999) and to quantify ampli®cates of AChR a-and g-subunit message on gels using the NIH software scanning program (Fig. 2) . This technique has been shown to be applicable to small biopsies (<150 ng of extractable RNA) as is typically available from patients with myositis, neurogenic or non-in¯ammatory myopathies. In a double-blinded study, the g/a ratios were calculated for muscle biopsies derived from patients with neurogenic disorders (n = 15), non-in¯ammatory myopathies (n = 23) and in¯ammatory myopathies (n = 8), and compared with results from histologically-normal muscle biopsies (n = 31). The cases investigated are listed in Table 1 and the results presented in Fig. 3 .
Histologically normal muscle typically exhibited an g/a ratio between 0.06 and 0.3 (mean value T SD: 0.17 T 0.068) (Fig. 3) . In all muscle biopsies with neurogenic disorders (n = 15), the g/a ratios were >0.69, and in seven biopsies they (Table 1) . The difference between values in neurogenic and normal muscles was highly signi®cant (P < 0.0001, Mann±Whitney U-test).
The g/a ratios were less elevated in the muscle biopsies from patients with myogenic disorders, but taking the mean + 3SD of the normal biopsies (0.37) as the cut-off, 17 out of 23 of the non-in¯ammatory myopathies and ®ve out of eight of the in¯ammatory myopathies had raised values, and as a group each was signi®cantly different (P < 0.0001) from the normal values.
The g/a ratios did not correlate signi®cantly with the age of the patients (data not shown) or the localization of the muscle biopsy (Table 1) .
AChR g-subunit expression and muscle ®bre type
All muscle biopsies were examined for muscle ®bre type atrophy by conventional ATPase enzymhistochemistry. Some biopsies had predominantly type 1 ®bre atrophy whereas others showed predominantly type 2 ®bre atrophy, or modest degrees of both. There was a striking association between the relative amount of g-subunit AChR transcripts and the presence of type 1 ®bre atrophy (Table 1) . To examine in more detail the distribution of AChRs in atrophic muscle ®bres, AChR expression was investigated with a monoclonal antibody, M1B8, speci®c for the foetal AChR isoform, in patients with neurogenic disorders (n = 10), non-in¯amma-tory myopathy (n = 10), in¯ammatory myopathy (n = 6) and histologically normal muscle biopsies (n = 10). In Fig. 4 , strong positivity is shown in a biopsy from a patient with inclusion body myositis and a g/a ratio of 0.97 (Case 40) compared with absence of foetal AChR in histologicallynormal muscle with an g/a ratio of 0.14 ( Fig. 4A and B) .
In all muscle biopsies with g/a ratios >1.0 (n = 7, see Table 1 ), immunohistochemistry revealed strong immunoreactivity (+++) in large groups of angulated atrophic ®bres and ATPase staining of serial sections showed that all ®bres expressing the foetal AChR were atrophic type 1 muscle ®bres (Fig. 5) . All muscle biopsies with g/a ratios between 0.67 and 1.0 (n = 13, see Table 1 ) showed distinct immunoreactivity (++/+) on the surface of scattered single atrophic muscle ®bres, all of which also belonged to the type 1 ®bre subtype (Fig. 6A) . By contrast, there was no reactivity on angulated atrophic type 2 ®bres ( Fig. 5B and C) or on single rounded and polygonal atrophic type 2 ®bres ( Fig. 6A  and B) . Moreover, all muscle biopsies with g/a ratios <0.67 (n = 6) lacked detectable immunoreactivity for the g-subunit of the AChR, irrespective of the presence of ®bre type atrophy (Table 1) .
AChR g-subunit expression and increased transcription
In situ hybridization was performed on muscle sections, with identi®cation of the ®bre types and AChR protein expression on serial sections. In all muscle biopsies tested with g/a ratios >0.67 (n = 10), atrophic, M1B8-positive, muscle ®bres (Fig. 7A, above) were positive for g-subunit RNA by in situ , and the immunohistochemical staining with the anti-foetal AChR mAb, M1B8, in a biopsy with two groups of angulated atrophic muscle ®bresÐone with (arrowheads) and one without (arrows) positive immunhistochemical staining. In the higher magni®cations of these areas (C and D), the immunohistochemically positive angulated ®bres showing outer cell membrane staining were all identi®ed as type 1 muscle ®bres (D), whereas the immunohistochemically negative angulated ®bres belonged to the type 2 muscle ®bres (C). hybridization (Fig. 7A, below) . By contrast, there was no evidence by in situ hybridization for AChR g-subunit expression in those muscle biopsies that lacked type 1 ®bre atrophy (n = 15, see Table 1 )Ðincluding six muscle biopsies from histologically normal muscle (Fig. 7B and C )Ðregard-less of the presence of type 2 ®bre atrophy.
Discussion
We used molecular and immunological techniques to measure AChR g-subunit expression in muscle biopsies from neurogenic and primary myopathic disorders. Expression of the g AChR gene was most marked in chronic neurogenic disorders, but occurred to a lesser extent in biopsies from patients with in¯ammatory and primary myopathic muscle diseases. Surprisingly, expression of the foetal AChR isoform, identi®ed by immunohistochemistry or by in situ hybridization for the g-subunit, was restricted in all cases to type 1 muscle ®bres. This striking ®nding suggests that denervation-induced AChR expression in humans is regulated in a manner which depends on the ®bre type.
We ®nd a/g duplex RT±PCR, which can be performed on small amounts of tissue, a very useful technique for investigation of muscle biopsies. g/a ratios >1.0 are strongly in favour of a neurogenic disorder, while ratios <0.67 appear to exclude neurogenic disorders. Nevertheless, almost all values in biopsies from in¯ammatory or non-in¯ammatory myopathies had increased g/a ratios compared with histologically normal biopsies. Although the extent of AChR gsubunit RNA and protein hyperexpression in these cases was usually much lower than in neurogenic disorders (Fig. 3 , Table 1 ), these results are consistent with clinical and electrophysiological studies that frequently reveal mild to moderate degrees of`denervation' among in¯ammatory (Figarella-Branger et al., 1992; Heuss et al., 1995) and noninfammatory myopathies (Bradley et al., 1978) . The marked increase in AChR g-subunit message and foetal AChR protein con®rms previous ®ndings in chronically denervated human muscle (Tsay and Schmidt, 1989) , but differs from results in rat models of denervation where AChR g-subunit transcription is only transiently up-regulated (Witzemann et al., 1991) .
An unexpected result was the lack of signi®cant upregulation of steady state AChR a-subunit RNA levels as measured by RNase protection assay or RT±PCR in any of the muscle biopsies studied irrespective of the underlying pathology (Fig. 1) . This is in apparent contrast to ®ndings by MacLennan et al. (1997) , who showed considerable upregulation of all AChR subunits in one sample of partially denervated gastrocnemius (the muscle most often biopsied in our neurogenic cases). However, the tissue from their diabetic patient was obtained from an amputated leg, and the effects of the diabetic neuropathy would have been complicated by ischaemia. It is possible that the two combined produce upregulation of all AChR subunits, whereas during chronic denervation the effects are attenuated (Adams et al., 1995) . Two important questions are how the g-subunit is upregulated independently of the a-subunit, and how the foetal AChR (a 2 bgd) is formed if only the g-subunit is up-regulated. An explanation for the latter may be that the a and other subunits are usually present in excess; for instance, only in the seven neurogenic cases was there more g-subunit than asubunit expression. The former question, and the distribution of g-subunit expression along the length of individual muscle ®bres, will require further investigation.
Our most striking ®nding was that the up-regulation of AChR g-subunit RNA and foetal AChR was only found on type 1 ®bres, as shown by both immunohistochemistry and in situ hybridization. Consequently, states of isolated or pre- LGMD. Some scattered single atrophic muscle ®bres (black arrowheads and red arrows) show immunoreactivity for the foetal AChR, while in (B) serial sections of a muscle biopsy from a patient with PROMM other (rounded) and polygonal atrophic ®bres remain negative (blue and black arrows). In the ATPase reaction, all mAb M1B8 positive atrophic ®bres again belonged to the type 1 ®bre subtype (black arrowheads and red arrows), while all anti-gAChR mAb M1B8 negative ®bres are type 2 ®bres resembling myogenic atrophic ®bres (blue and black arrows) (Q400).
dominantly type 2 muscle ®bre atrophy, like Becker muscular dystrophy (Fig. 6) , were not associated with AChR g-subunit hyperexpression (Table 1) as previously reported in muscle atrophy associated with ageing (Lexell and Downham, 1992; Lexell, 1993 Lexell, , 1995 or immobilization (Fisher and Brown, 1998; Ibebunjo and Martyn, 1999) . Particularly striking was the lack of AChR g-subunit expression by atrophic type 2 ®bres side-by-side with AChR g-subunit hyperexpresion in atrophic type 1 ®bres in severe neurogenic muscle atrophy (Fig. 5), dystrophy (Fig. 6A ) and inclusion body myositis (Fig. 4A ) that are all known to affect both ®bre types (Schroder and Adams, 1968; Askanas et al., 1994) . The latter observations, therefore, indicate that transcription of the AChR g-subunit gene is not only regulated by innervationdependent factors, but modi®ed by factors that are involved in muscle ®bre type determination. Indeed, our observation that innervation and ®bre type can operate in concert to regulate gene expression is not unprecedented. In contrast to the up-regulation of the foetal AChR in type 1 muscle ®bres following denervation, it has been reported that denervation selectively down-regulates neurotrophin-4 (NT-4) expression in type 1 muscle ®bres (Funakoshi et al., 1995; Wells et al., 1999; Belluardo et al., 2001) The molecular mechanisms underlying the ®bre-type bias of AChR expression are still unclear. However, many differences are beginning to emerge regarding the ontogeny and control of the different ®bre types and ®bre type speci®c gene expression. Signalling molecules such as insulin growth factor (IGF), protein kinase C (PKC), calcineurin, p70S6k, NFAT and MEF2 are thought to play a role in inducing type 1 versus type 2 muscle ®bre development ( Immunohistochemistry with foetal ACHR mAb M1B8 on serial sections from muscle biopsies from PNP (A), PROMM (B) and normal muscle (C) compared with in situ hybridization with the AChR g-subunit probe (below). In A, the mAb M1B8 positive atrophic ®bres (arrows) also show a strong and speci®c signal by in situ hybridization (arrows). By contrast, neither the atrophic mAb M1B8 negative ®bres in B (arrow) nor any other normal muscle ®bres in (B) or (C) showed a speci®c signal with in situ hybridization (Q400).
AML-1 after denervation appears to occur independent of ®bre type (Zhu et al., 1994) . Although there is still considerable uncertainty about many aspects of the pathways concerned (Olson and Williams, 2000; Buckingham 2001 ), activation of PKC isoforms appears to be important in development of type 1 ®bres (DiMario and Funk, 1999) . Conversely, calcium-induced activation of PKC is also thought to be critical for reducing extra-junctional AChR expression after innervation (Montgomery et al., 2000) and lack of calcium-induced PKC activation is thought to upregulate AChR g-subunit gene expression by extra-junctional nuclei when muscle activity is reduced by denervation. Thus, it is likely that factors other than the activity of calciumdependent PKC isoforms are involved in regulation of genes that de®ne the phenotype of type 1 ®bres in denervated muscle. It will be interesting to look at the expression of growth factors, PKC isoforms and the various transcription factors in these human muscle biopsies.
Our results emphasize how little is known about the phenotypic characteristics of the muscle ®bres and the factors that in¯uence them in various disease states. They raise the possibility that expression of those proteins involved in the structural integrity of the motor endplate and sarcolemma may be differentially regulated. In Duchenne muscular dystrophy, there is reduced muscle glycolytic activity and in its mouse model, the mdx/utrn-/-double knock-out mouse, which lacks both dystrophin and utrophin, there is a shift towards type 1 ®bre types (Rafael et al., 2000) . In mdx and the double knock-out mice, the AChR distribution at the neuromuscular junction is patchy with discontinuous AChR staining (Rafael et al., 2000; Minatel et al., 2001 ). This suggests that in dystrophic or regenerating (DiMario and Funk, 1999) muscles, changes in expression of proteins that are speci®c to ®bre type, the sarcolemma and the neuromuscular junction proteins may go in parallel. Similarly, in the AChR de®ciency syndrome caused by AChR e-subunit mutations (Engel et al., 1999; Croxen et al., 2001) , the AChR g-subunit is thought to be crucial for maintaining neuromuscular transmission, but the present study suggests that its expression might be restricted to type 1 ®bres. A systematic study of expression of the factors involved in controlling expression of all these proteins could lead to a better understanding of the pathogenesis of the associated disorders. It could also be of relevance to any treatment protocols aimed at up-regulating these or compensatory proteins.
